Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated|Treatment of autoimmune hepatitis (AIH)" in comments (approximate match)

Showing 1 - 1 of 1 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PREIMPLANTATION FACTOR

3K6A6FJ98O

Search for Structure

Status:

Investigational

Source:

NCT03593421: Phase 2 Interventional Withdrawn Panel Reactive Antibodies

(2019)

Source URL:

https://clinicaltrials.gov/ct2/show/NCT03593421

Class (Stereo):

CHEMICAL (ABSOLUTE)

Structure of PREIMPLANTATION FACTOR

ABSOLUTE

PREIMPLANTATION FACTOR

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1